EXHIBIT 10.6 VOTING AGREEMENT THIS VOTING AGREEMENT (the "Voting Agreement") is entered into effective as of June 18, 2003, by and between Roger D. Hurst ("Hurst"), and AspenBio, Inc., a Colorado corporation (the "Company"). WHEREAS, Hurst owns...Voting Agreement • March 29th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
ARTICLE I THE LOAN --------Loan Agreement • March 26th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
ARTICLE 1 TERM OF EMPLOYMENT ------------------Executive Employment Agreement • August 30th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
RECITALSShareholders Agreement • April 12th, 2002 • Aspenbio Inc • Colorado
UNDERWRITING AGREEMENT between ASPENBIO PHARMA, INC. and AEGIS CAPITAL CORP., as Representative of the Several UnderwritersUnderwriting Agreement • November 16th, 2012 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
The undersigned, AspenBio Pharma, Inc., a corporation formed under the laws of the State of Colorado (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of AspenBio Pharma, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
EXHIBIT 10.18(b) PLEDGE AGREEMENT PLEDGE AGREEMENT (the "AGREEMENT"), dated as of the 5th day of July, 2002 between AspenBio, Inc., a Colorado corporation ("PLEDGOR"), and Michael S. Smith ("PLEDGEE"). WHEREAS, Pledgee has loaned to Pledgor $500,000...Pledge Agreement • July 8th, 2002 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
COMMON STOCK PURCHASE WARRANT VENAXIS, inc.Common Stock Purchase Warrant • May 23rd, 2013 • Venaxis, Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Original Issue Date”) and on or prior to 5:30 p.m., New York City time, on the date that is ___ years following the Original Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Venaxis, Inc., a Colorado corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of ______ share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 28th, 2011 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 23, 2011, between AspenBio Pharma, Inc., a Colorado corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Riot Blockchain, Inc. Shares of Common Stock (no par value per share) Controlled Equity OfferingSM Sales AgreementRiot Blockchain, Inc. • March 31st, 2022 • Services-computer processing & data preparation • New York
EXHIBIT 10.4(a) CONSULTING AGREEMENT This Consulting Agreement (the "Agreement") is entered into effective as of December 28, 2001, by and between AspenBio, Inc., a Colorado corporation (the "Company") and Cambridge Holdings, Ltd., a Colorado...Consulting Agreement • April 12th, 2002 • Aspenbio Inc • Colorado
Riot Blockchain, Inc. Shares of Common Stock (no par value per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 31st, 2021 • Riot Blockchain, Inc. • Services-computer processing & data preparation • New York
RECITALSInvestor Rights Agreement • July 8th, 2002 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
EXHIBIT 10.22 ------------- LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (the "Lock-up Agreement") is entered into effective as of June 9, 2003, by and between Roger D. Hurst (the "Shareholder"), a shareholder of AspenBio, Inc., a Colorado corporation...Lock-Up Agreement • June 24th, 2003 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
Venaxis, Inc. 8,335,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • April 3rd, 2014 • Venaxis, Inc. • In vitro & in vivo diagnostic substances • New York
Venaxis, Inc., a Colorado corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 8,335,000 shares (the “Underwritten Shares”) of common stock, no par value per share, of the Company (the “Common Stock”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 1,250,250 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
RECITALSDistribution Agreement • April 7th, 2003 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Georgia
EXHIBIT 10.25 EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 16th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Missouri
ASPENBIO, INC.Stock Option Agreement • April 12th, 2002 • Aspenbio Inc
2% CONVERTIBLE NOTE DUE [____], 2018Bioptix, Inc. • March 17th, 2017 • In vitro & in vivo diagnostic substances • New York
THIS CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Notes of Bioptix, Inc., a Colorado corporation, (the "Borrower"), having its principal place of business at 1775 38th Street, Boulder CO 80301, due [____], 2018 (this note, the "Note" and, collectively with the other notes of such series, the "Notes").
for the purchase of Units Each Unit consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock ofCommon Stock and Warrant Purchase Agreement • August 12th, 2005 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
ARTICLE 1 TERM OF EMPLOYMENT ------------------Employment Agreement • January 25th, 2005 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
PLACEMENT AGENCY AGREEMENT December 23, 2011Placement Agency Agreement • December 28th, 2011 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
Exhibit 10.25 (a) AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement is entered into effective December 8, 2004 by and between AspenBio, Inc. (the "Company") and Roger Hurst ("Hurst"). WHEREAS, the Board of Directors and Hurst...Employment Agreement • December 10th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances
AMENDMENT TO AGREEMENT TO REVISE STOCKHOLDING, AMEND DEBT AGREEMENT AND ENTER INTO EMPLOYMENT AGREEMENTAgreement • August 16th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances
UNDERWRITING AGREEMENT between ASPENBIO PHARMA, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters ASPENBIO PHARMA, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • June 20th, 2012 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
The undersigned, AspenBio Pharma, Inc., a corporation formed under the laws of the State of Colorado (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of AspenBio Pharma, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
COMMON STOCK PURCHASE WARRANT RIOT BLOCKCHAIN, INC.Riot Blockchain, Inc. • February 1st, 2019 • In vitro & in vivo diagnostic substances • Kansas
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the funding of that certain senior secured convertible promissory note dated January 28, 2019, in the original principal amount of up to [$________] by the Company (as defined below) to the Lender (as defined below)) (the “Note”), [___________] (the “Lender” and including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time during the Exercise Period, to purchase from Riot Blockchain, Inc., a Nevada corporation (the “Company”), up to [_________] shares of Common Stock (as defined below) (the “Warrant Shares”) at the Exercise Price per share then in effect. The number of Warrant Shares for which this Warrant may be exercised is subject to adjustment in accordance with the terms hereof. This Warrant is issued by the Company as of the date hereof pursuant to the
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 19th, 2017 • Riot Blockchain, Inc. • In vitro & in vivo diagnostic substances
THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is made as of _________ 2017, among Riot Blockchain, Inc., a Nevada (the "Company"), the investor signatory hereto (the "Investor"). Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Purchase Agreement (as defined below).
RECITALSTechnology Transfer Agreement • April 12th, 2002 • Aspenbio Inc • Wyoming
2,409,639 Units ASPENBIO PHARMA, INC. PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • April 30th, 2010 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
BIOPTIX, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIESBioptix, Inc. • February 8th, 2017 • In vitro & in vivo diagnostic substances • New York
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the "Securities"), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
EXHIBIT 10.16(c) THIS FORM AS IMPORTANT LEGAL CONSEQUENCES AND THE PARTIES SHOULD CONSULT LEGAL AND TAX OR OTHER COUNSEL BEFORE SIGNING. AGREEMENT TO AMEND/EXTEND CONTRACTAspenbio Inc • June 6th, 2002 • In vitro & in vivo diagnostic substances • Colorado
RECITALSAspenbio Inc • April 12th, 2002
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • November 13th, 2017 • Riot Blockchain, Inc. • In vitro & in vivo diagnostic substances • New York
This SHARE EXCHANGE AGREEMENT (this “Agreement”), dated as of [____], 2017, is by and among Riot Blockchain, Inc., a Nevada corporation (the “Parent”), Kairos Global Technology, Inc., a Nevada corporation (the “Company”), and the shareholders of the Company (each a “Shareholder” and collectively the “Shareholders”). Each of the parties to this Agreement is individually referred to herein as a “Party” and collectively as the “Parties.”
Ÿ ] Shares1 Venaxis, Inc. Common Stock PURCHASE AGREEMENTPurchase Agreement • May 20th, 2013 • Venaxis, Inc. • In vitro & in vivo diagnostic substances • New York
Venaxis, Inc., a Colorado corporation (the “Company”), proposes to sell to Piper Jaffray & Co. (the “Underwriter”) an aggregate of [ Ÿ ] shares (the “Firm Shares”) of Common Stock, no par value per share (the “Common Stock”), of the Company. The Firm Shares consist of [ Ÿ ] authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the Underwriter an option to purchase up to [ Ÿ ] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”
FORM OF COMMON STOCK PURCHASE WARRANTBioptix, Inc. • March 17th, 2017 • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, [______] or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Issuance Date (the "Initial Exercise Date") and on or prior to the close of business on the thirty six (36) month anniversary of the Initial Exercise Date (the "Termination Date") but not thereafter, to subscribe for and purchase from BIOPTIX, INC., a Colorado corporation (the "Company"), up to [____] shares (as subject to adjustment hereunder, the "Warrant Shares") of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Riot Platforms, Inc. Shares of Common Stock (no par value per share) Controlled Equity OfferingSM Sales AgreementRiot Platforms, Inc. • August 9th, 2023 • Finance services • New York
Riot Platforms, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co., B. Riley Securities, Inc., BTIG, LLC, Roth Capital Partners, LLC, Compass Point Research & Trading, LLC, Northland Securities, Inc., Moelis & Company LLC, and Stifel Nicolaus Canada Inc. (collectively, the “Agents,” and individually, an “Agent”), as follows:
